Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
Autor:
Simon, Iris
; Perales, Sonia
; Casado-Medina, Laura
; Rodríguez-Martínez, Alba
; Garrido-Navas, M. Carmen
; Puche-Sanz, Ignacio
; Diaz-Mochon, Juan J.
; Alaminos, Clara
; Lupiañez, Pablo
; Lorente, José Antonio
; Serrano, M. José
; Real, Pedro J.
Fecha:
2021Palabra clave:
Revista / editorial:
CancersTipo de Ítem:
Articulo Revista IndexadaDirección web:
https://www.mdpi.com/2072-6694/13/6/1483Resumen:
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status (CRPC) is commonly developed. The expression of androgen receptor (AR) alternative splicing isoforms (AR‐V7 and AR‐V9) has been associated to CRPC. However, resistance mechanisms to novel NHAs are not yet well understood. Androgen‐dependent PCa cell lines were used to generate resistant models to ADT only or in combination with Abiraterone and/or Enzalutamide (concomitant models). Functional and genetic analyses were performed for each resistance model by real‐time cell monitoring assays, flow cytometry and RT‐qPCR. In androgen‐dependent PCa cells, the administration of Abiraterone and/or Enzalutamide as first‐line treatment involved a critical inhibition of AR activity associated with a significant cell growth inhibition. Genetic analyses on ADT‐resistant PCa cell lines showed that the CRPC phenotype was accompanied by overexpression of AR full‐length and AR target genes, but not necessarily AR‐V7 and/or AR‐V9 isoforms. These ADT resistant cell lines showed higher proliferation rates, migration and invasion abilities. Importantly, ADT resistance induced cross‐resistance to Abiraterone and/or Enzalutamide. Similarly, concomitant models possessed an elevated expression of AR full‐length and proliferation rates and acquired cross‐resistance to its alternative NHA as second‐ line treatment.
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
38 |
60 |
51 |
12 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers
Garrido-Navas, M. Carmen ; García-Díaz, Abel; Molina-Vallejo, María Pilar; González-Martínez, Coral; Alcaide Lucena, Miriam; Cañas-García, Inés; Bayarri, Clara; Delgado, Juan Ramón; González, Encarna; Lorente, José Antonio; Serrano, M. José (Cancers, 11/2020)Being minimally invasive and thus allowing repeated measures over time, liquid biopsies are taking over traditional solid biopsies in certain circumstances such as those for unreachable tumors, very early stages or treatment ... -
I Congreso Español de Videojuegos 2022
González Calero, Pedro Antonio; Gómez Martín, Marco Antonio; Gómez Martín, Pedro Pablo; Gutiérrez Manjón, Sergio; Gutiérrez Sánchez, Pablo; Peinado, Federico; Sánchez-Ruiz Granados, Antonio; Barbancho, Isabel; Blanco Bueno, Carlos; Botella Nicolás, Ana María; Chover, Miguel; Díaz Álvarez, Josefa; Echeverría, Jorge; Fernández Leiva, Antonio J.; Fernández Ruiz, Marta; Gallego-Durán, Francisco; García Sánchez, Pablo; Gutiérrez Vela, Francisco L; Lara-Cabrera, Raúl; León, Carlos; Moreno, Jorge L.; Lozano Muñoz, Alejandro; Mayor, Jesús; Medina Medina, Nuria; Mejías-Climent, Laura; Mora, Antonio M; Munarriz, Jaime; Patow, Gustavo A.; Sagredo-Olivenza, Ismael; Salinas, María-José; Sanchez I. Peris, Francesc Josep; Sánchez-Ruiz, Antonio A; Shliakhovchuk, Elena; Tejada, Jesus (CEUR Workshop Proceedings, 2022){Resumen no disponible] -
Impact of COVID-19 Lockdown in Eating Disorders: A Multicentre Collaborative International Study
Baenas, Isabel; Etxandi, Mikel; Munguía, Lucero; Granero, Roser; Mestre-Bach, Gemma ; Sánchez, Isabel; Ortega, Emilio; Andreu, Alba; Moize, Violeta L.; Fernández-Real, Jose-Manuel; Tinahones, Francisco J.; Diéguez, Carlos; Frühbeck, Gema; Le Grange, Daniel; Tchanturia, Kate; Karwautz, Andreas; Zeiler, Michael; Imgart, Hartmut; Zanko, Annika; Favaro, Ángela; Claes, Laurence; Shekriladze, Ia; Serrano‐Troncoso, Eduardo; Cecilia-Costa, Raquel; Rangil, Teresa; Loran Meler, Maria Eulalia; Soriano‐Pacheco, José; Carceller‐Sindreu, Mar; Navarrete, Rosa; Lozano, Meritxell; Linares, Raquel; Gudiol, Carlota; Carratala, Jordi; Plana, María T.; Graell, Montserrat; González-Parra, David; Gómez-del Barrio, José A.; Sepúlveda, Ana R.; Sánchez-González, Jéssica; Machado, Paulo PP; Håkansson, Anders; Túry, Ferenc; Pászthy, Bea; Stein, Daniel; Papezová, Hana; Gricova, Jana; Bax, Brigita; Borisenkov, Mikhail F.; Popov, Sergey V.; Gubin, Denis G.; Petrov, Ivan M.; Isakova, Dilara; Mustafina, Svetlana V.; Kim, Youl‐Ri; Nakazato, Michiko; Godart, Nathalie; van Voren, Robert; Ilnytska, Tetiana; Chen, Jue; Rowlands, Katie; Voderholzer, Ulrich; Monteleone, Alessio M.; Treasure, Janet; Jiménez-Murcia, Susana; Fernández-Aranda, Fernando (Nutrients, 01/2022)Background. The COVID-19 lockdown has had a significant impact on mental health. Patients with eating disorders (ED) have been particularly vulnerable. Aims. (1) To explore changes in eating-related symptoms and general ...